Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
James Ge
AddedMar 31, 2024
UpdatedMay 31, 2026
James Ge

James Ge

Founder, Kalidex Pharmaceuticals

CrunchbaseLinkedIn

James Ge's Career

Kalidex Pharmaceuticals
Kalidex Pharmaceuticals

Menlo Park, CA, US

Founder
Recida Therapeutics
Recida Therapeutics

Menlo Park, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

James Ge's Career

Kalidex Pharmaceuticals
Kalidex Pharmaceuticals
$15M02010Menlo Park, CA, US
Founder

Leadership at Kalidex Pharmaceuticals

Dennis PodlesakDennis PodlesakBoard Member
Brent AhrensBrent AhrensBoard Member

Similar to Kalidex Pharmaceuticals

Nexcida TherapeuticsNexcida TherapeuticsMenlo Park, CA, USAntibiotics, Therapeuticsest. 2014Nexcida TherapeuticsMenlo Park, CA, US · est. 2014

Innovative Menlo Park-based medical organization developing novel antibiotics for drug-resistant bacteria.

Seed · $2.8M50
Bioxiness PharmaceuticalsBioxiness PharmaceuticalsHercules, CA, USAntimicrobial Compoundsest. 2007Bioxiness PharmaceuticalsHercules, CA, US · est. 2007

Bioxiness Pharmaceuticals: A CA-based firm developing novel antimicrobial compounds for severe infections.

Pre-Seed · $804.6k5
Recida TherapeuticsRecida TherapeuticsMenlo Park, CA, USPharmaceuticalsest. 2016Recida TherapeuticsMenlo Park, CA, US · est. 2016

Recida Therapeutics, Inc.: A biopharmaceutical firm developing treatments for antibiotic-resistant infections.

Series A · $18.6M5
Cardeas PharmaCardeas PharmaSeattle, WA, USAntibiotics, Pharmaceuticalsest. 2010Cardeas PharmaSeattle, WA, US · est. 2010

Cardeas Pharma: Specializing in developing inhaled antibiotics for respiratory infections.

Series B · $80M30
Recida Therapeutics
Recida Therapeutics
Series A$18.6M52016Menlo Park, CA, US
Co-Founder

Leadership at Recida Therapeutics

Patrick HeronPatrick HeronBoard Member
David SocksDavid SocksBoard Member

Similar to Recida Therapeutics

Recreo PharmaceuticalsRecreo PharmaceuticalsSuperior, CO, USAntibody Therapeuticsest. 2013Recreo PharmaceuticalsSuperior, CO, US · est. 2013

Recreo Pharmaceuticals: Innovating antibody therapeutics to combat antibiotic resistance.

Seed · $3M5
Nexcida TherapeuticsNexcida TherapeuticsMenlo Park, CA, USAntibiotics, Therapeuticsest. 2014Nexcida TherapeuticsMenlo Park, CA, US · est. 2014

Innovative Menlo Park-based medical organization developing novel antibiotics for drug-resistant bacteria.

Seed · $2.8M50
X-Biotix TherapeuticsX-Biotix TherapeuticsWaltham, MA, USAntibioticsest. 2016X-Biotix TherapeuticsWaltham, MA, US · est. 2016

X-Biotix Therapeutics: A biotech firm innovating antibiotic solutions for multi-drug-resistant pathogens.

Series A · $7M9
ReCode TherapeuticsReCode TherapeuticsMenlo Park, CA, USGenetic Therapiesest. 2015ReCode TherapeuticsMenlo Park, CA, US · est. 2015

ReCode Therapeutics: Developing targeted genetic therapies for life-limiting respiratory diseases.

Series B · $521.8M143

People Similar to James Ge

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · KakaoTomer YogevTomer YogevCo-Founder · DyMyndKen ReimerKen ReimerFounder · ECOWayne ChanWayne ChanCo-Founder · KabamJon HallettJon HallettCo-Founder · GridlineAdrian JamesAdrian JamesCo-Founder · VolconKanwaljit SinghKanwaljit SinghCo-Founder · Fireside Ventures